Blinatumomab (Blincyto) for acute lymphoblastic leukemia.
Blinatumomab (Blincyto) was effective in inducing a complete remission in 33% of patients with relapsed or refractory Philadelphia chromosome-negative (Ph-) B-cell precursor acute lymphoblastic leukemia (ALL). Grade 3 or 4 adverse effects occur frequently.